Thermo Fisher Scientific Inc. $TMO Shares Bought by Arjuna Capital

Arjuna Capital increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 64.5% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 6,583 shares of the medical research company’s stock after acquiring an additional 2,582 shares during the period. Thermo Fisher Scientific makes up about 0.9% of Arjuna Capital’s investment portfolio, making the stock its 24th largest position. Arjuna Capital’s holdings in Thermo Fisher Scientific were worth $3,815,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the business. JPL Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth about $28,000. Beacon Financial Strategies CORP acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. Olistico Wealth LLC bought a new position in Thermo Fisher Scientific in the 4th quarter valued at $29,000. Cloud Capital Management LLC bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth $31,000. Finally, HFM Investment Advisors LLC lifted its holdings in Thermo Fisher Scientific by 341.7% during the fourth quarter. HFM Investment Advisors LLC now owns 53 shares of the medical research company’s stock worth $31,000 after acquiring an additional 41 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Morgan Stanley reissued an “overweight” rating and issued a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $616.10.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $438.16 on Friday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $643.99. The firm has a market cap of $162.83 billion, a P/E ratio of 24.09, a P/E/G ratio of 1.98 and a beta of 0.88. The firm has a 50-day moving average of $486.00 and a 200-day moving average of $542.12. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. During the same quarter last year, the firm earned $5.15 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $63,499,170. The trade was a 3.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.